N@N

Ista Pharmaceuticals Inc (NASDAQ:ISTA), Up By 15.67% ($1.10) From $7.020 After BUYINS.NET Report Predicted Stock Would Go Up Du

^{Published on 2012-01-17 07:43:06 - WOPRAI}
 

January 17, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, December 22nd 2011 stating that Ista Pharmaceuticals Inc (NASDAQ:ISTA) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=ista&id=224975

At the time this story was written, Ista Pharmaceuticals Inc (NASDAQ:ISTA) is Up By $1.10 (15.67%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Ista Pharmaceuticals Inc (NASDAQ:ISTA) - ISTA Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets remedies for diseases and conditions of the eye in the United States. It provides products to treat diseases of the eye and allergies; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company offers Xibrom for the treatment of ocular inflammation and pain following cataract surgery; Bepreve to treat ocular itching associated with allergic conjunctivitis; Istalol for the treatment of Glaucoma; and Vitrase for use as a spreading agent. Its products under development include XiDay, which completed Phase III confirmatory clinical study for the treatment of ocular inflammation and pain following cataract surgery; T-Pred that completed Phase III bioequivalence study for the treatment of steroid-responsive inflammatory ocular conditions; Bromfenac lower concentration, which completed Phase II study to treat dry eye syndrome; Ecabet Sodium, a Phase IIb product for the treatment of dry eye syndrome; and Bepotastine Nasal to treat allergic rhinitis. The companys products under development also comprise a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost, a prostaglandin, for the treatment of glaucoma. ISTA Pharmaceuticals, Inc. sells its products primarily to drug wholesalers, retailers, and distributors, including large chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. The company was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. ISTA Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Irvine, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net